We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07654374

Obesity & weight · Phase 3 · Recruiting now

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374 · Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

What this trial means for you

This study is recruiting now at 74 US sites. It's studying aleniglipron, aleniglipron, aleniglipron, Placebo for obesity, overweight, chronic weight management.

Who can joinAll sexes, 18 Years – 79 Years
Healthy volunteersAccepted
What you'd takealeniglipron, aleniglipron, aleniglipron, Placebo
Study length~2.2 years overall
Planned participants1,100
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Signed Informed Consent * Have a BMI ≥27.0 kg/m2 at Screening * Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening Exclusion Criteria: * Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM. * Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Self-reported change in body weight \>5 kg (11 pounds) within 3 months before Screening. * Have prior or planned surgical or non-surgical treatment for obesity.

Study sites by state

Alabama

  • ACCOMPLISH-2 Research Site, Birmingham · Recruiting now

Arizona

  • ACCOMPLISH-2 Research Site, Chandler · Recruiting now
  • ACCOMPLISH-2 Research Site, Phoenix · Opening soon
  • ACCOMPLISH-2 Research Site, Sun City West · Opening soon
  • ACCOMPLISH-2 Research Site, Tucson · Opening soon

Arkansas

  • ACCOMPLISH-2 Research Site, Little Rock · Opening soon

California

  • ACCOMPLISH-2 Research Site, Escondido · Opening soon
  • ACCOMPLISH-2 Research Site, Fountain Valley · Opening soon
  • ACCOMPLISH-2 Research Site, La Jolla · Recruiting now
  • ACCOMPLISH-2 Research Site, Lake Forest · Opening soon
  • ACCOMPLISH-2 Research Site, Rolling Hills Estates · Opening soon
  • ACCOMPLISH-2 Research Site, San Diego · Recruiting now
  • ACCOMPLISH-2 Research Site, Tustin · Opening soon

Connecticut

  • ACCOMPLISH-2 Research Site, Waterbury · Opening soon

Florida

  • ACCOMPLISH-2 Research Site, Clearwater · Recruiting now
  • ACCOMPLISH-2 Research Site, Fort Myers · Recruiting now
  • ACCOMPLISH-2 Research Site, Jacksonville · Opening soon
  • ACCOMPLISH-2 Research Site, Leesburg · Recruiting now
  • ACCOMPLISH-2 Research Site, Miami · Opening soon
  • ACCOMPLISH-2 Research Site, Ocala · Opening soon
  • ACCOMPLISH-2 Research Site, Ocoee · Opening soon
  • ACCOMPLISH-2 Research Site, Pembroke Pines · Opening soon

Georgia

  • ACCOMPLISH-2 Research Site, Atlanta · Recruiting now
  • ACCOMPLISH-2 Research Site, Columbus · Opening soon
  • ACCOMPLISH-2 Research Site, Lawrenceville · Opening soon
  • ACCOMPLISH-2 Research Site, Union City · Opening soon
  • ACCOMPLISH-2 Research Site, Woodstock · Recruiting now

Idaho

  • ACCOMPLISH-2 Research Site, Meridian · Recruiting now

Iowa

  • ACCOMPLISH-2 Research Site, Des Moines · Recruiting now
  • ACCOMPLISH-2 Research Site, Iowa City · Opening soon

Kansas

  • ACCOMPLISH-2 Research Site, Wichita · Recruiting now

Maryland

  • ACCOMPLISH-2 Research Site, Silver Spring · Recruiting now

Massachusetts

  • ACCOMPLISH-2 Research Site, Methuen · Recruiting now

Minnesota

  • ACCOMPLISH-2 Research Site, Mankato · Recruiting now
  • ACCOMPLISH-2 Research Site, Minneapolis · Recruiting now

Mississippi

  • ACCOMPLISH-2 Research Site, Gulfport · Recruiting now
  • ACCOMPLISH-2 Research Site, Ridgeland · Opening soon

Missouri

  • ACCOMPLISH-2 Research Site, Chesterfield · Opening soon
  • ACCOMPLISH-2 Research Site, City of Saint Peters · Recruiting now
  • ACCOMPLISH-2 Research Site, Hazelwood · Recruiting now
  • ACCOMPLISH-2 Research Site, Springfield · Recruiting now
  • ACCOMPLISH-2 Research Site, St Louis · Opening soon

Montana

  • ACCOMPLISH-2 Research Site, Missoula · Recruiting now

Nebraska

  • ACCOMPLISH-2 Research Site, Omaha · Opening soon

Nevada

  • ACCOMPLISH-2 Research Site, Las Vegas · Opening soon

New York

  • ACCOMPLISH-2 Research Site, Albany · Opening soon
  • ACCOMPLISH-2 Research Site, Albany · Opening soon
  • ACCOMPLISH-2 Research Site, Brooklyn · Opening soon
  • ACCOMPLISH-2 Research Site, The Bronx · Opening soon

North Carolina

  • ACCOMPLISH-2 Research Site, Charlotte · Recruiting now
  • ACCOMPLISH-2 Research Site, Durham · Opening soon
  • ACCOMPLISH-2 Research Site, Fayetteville · Opening soon
  • ACCOMPLISH-2 Research Site, Morehead City · Opening soon
  • ACCOMPLISH-2 Research Site, Winston-Salem · Recruiting now

Ohio

  • ACCOMPLISH-2 Research Site, Columbus · Recruiting now

Oklahoma

  • ACCOMPLISH-2 Research Site, Moore · Recruiting now
  • ACCOMPLISH-2 Research Site, Tulsa · Opening soon
  • ACCOMPLISH-2 Research Site, Yukon · Opening soon

Oregon

  • ACCOMPLISH-2 Research Site, Portland · Recruiting now

Pennsylvania

  • ACCOMPLISH-2 Research Site, Philadelphia · Recruiting now

South Carolina

  • ACCOMPLISH-2 Research Site, Greer · Recruiting now

Tennessee

  • ACCOMPLISH-2 Research Site, Nashville · Opening soon

Texas

  • ACCOMPLISH-2 Research Site, Austin · Recruiting now
  • ACCOMPLISH-2 Research Site, Farmers Branch · Opening soon
  • ACCOMPLISH-2 Research Site, Houston · Recruiting now
  • ACCOMPLISH-2 Research Site, Houston · Recruiting now
  • ACCOMPLISH-2 Research Site, San Antonio · Recruiting now
  • ACCOMPLISH-2 Research Site, San Antonio · Opening soon
  • ACCOMPLISH-2 Research Site, Wylie · Opening soon

Utah

  • ACCOMPLISH-2 Research Site, Salt Lake City · Opening soon

Virginia

  • ACCOMPLISH-2 Research Site, Burke · Opening soon
  • ACCOMPLISH-2 Research Site, Manassas · Recruiting now
  • ACCOMPLISH-2 Research Site, Suffolk · Recruiting now

Washington

  • ACCOMPLISH-2 Research Site, Renton · Recruiting now

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth